Blockage of ghrelin-induced prolactin secretion in women by bromocriptine

Messini, Christina I.; Dafopoulos, Konstantinos; Chalvatzas, Nektarios; Georgoulias, Panagiotis; Anifandis, George; Messinis, Ioannis E.

doi:10.1016/j.fertnstert.2009.08.032

Cited by 14 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In women, ghrelin-stimulated prolactin production remains unchanged across the menstrual cycle (Messini et al, 2009a, b). However, D2-dopamine agonism (with bromocriptine) blocks the stimulating effect of ghrelin on prolactin in healthy women (Messini et al, 2010). This suggests that the mechanism of action of ghrelin on prolactin secretion may be mediated by inhibition of the dopaminergic system.…”

Section: Effects On Pituitary Prolactin Productionmentioning

confidence: 99%

The relationship between gut and adipose hormones, and reproduction

Comninos

Jayasena

Dhillo

2013

Human Reproduction Update

127

101

View full text Add to dashboard Cite

Gut and adipose hormones interact with the reproductive axis as well as with each other. While leptin and insulin have stimulatory effects and ghrelin has inhibitory effects on hypothalamic GnRH secretion, there is increasing evidence for their roles in other sites of the reproductive axis as well as evidence for the roles of other gut and adipose hormones in the complex interplay between nutrition and reproduction. As our understanding improves, so will our ability to identify and design novel therapeutic options for reproductive disorders and accompanying metabolic disorders.

show abstract

Section: Effects On Pituitary Prolactin Productionmentioning

confidence: 99%

The relationship between gut and adipose hormones, and reproduction

Comninos

Jayasena

Dhillo

2013

Human Reproduction Update

127

101

View full text Add to dashboard Cite

show abstract

“…The authors suggest that the increase in prolactin levels in women AD patients associated with lower craving may denote normalization of the chronically stimulated DA pathway during active drinking (Gessa et al 1985) and the HPA axis during alcohol withdrawal (Hillemacher et al 2005). Certainly, research performed on healthy women where the dopamine agonist drug bromocriptine was shown to block intravenous ghrelin stimulation of prolactin secretion in women should, be considered in AD patients to tease apart the importance of prolactin to craving in men and women (Messini et al 2010b). …”

Section: Reproductive Hormonesmentioning

confidence: 99%

The Relationship of Appetitive, Reproductive and Posterior Pituitary Hormones to Alcoholism and Craving in Humans

et al. 2012

View full text Add to dashboard Cite

“…Messini et al (14) investigated the effect of bromocriptine, which is a dopamine agonist similar to cabergoline on ghrelin-induced prolactin secretion in healthy premenopausal women. They demonstrated that bromocriptine block the stimulating effect of ghrelin on prolactin release (14). Thus, the insignificant lower levels of ghrelin in patients with remission may be related to the cabergoline effect of ghrelin on prolactin levels.…”

Section: Discussionmentioning

confidence: 99%

Hyperprolactinemia has no effect on plasma ghrelin levels in patients with prolactinoma

Delibaşı¹,

Arslan²,

Çakal³

et al. 2015

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

Material and Methods:Forty-four patients with prolactinoma, both newly diagnosed and undergoing cabergoline treatment, were included in this study. Age-and sex-matched healthy subjects were included in the control group. Serum fasting glucose, insulin, lipid profile, and ghrelin levels were measured. Homeostasis model assessment of insulin resistance (HOMA-IR) was also calculated. Body mass index (BMI) and total fat ratio (%) of all the participants were assessed by bioelectrical impedance analysis using TBF-310GS™ (Tanita Corporation, Tokyo, Japan). Results:Patients with prolactinoma demonstrated significantly higher serum levels of fasting insulin, triglyceride, and waist and hip circumference measurement. No significant difference was found between the fasting glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and HOMA-IR levels. BMI was significantly higher in the patients with prolactinoma than that in the control group (p<0.05). Additionally, the total body fat percentage was higher in the patients with prolactinoma than that in the control group; however, the difference was not significant (p>0.05). Furthermore, there was no significant difference in terms of the ghrelin levels between these groups. There was a correlation with serum ghrelin and growth hormone levels (p<0.02, rho=0.489). However, no significant correlation was obtained between serum prolactin or ghrelin levels and body fat percentage. Conclusion:According to the results of our study, ghrelin has no effect on weight gain in patients with prolactinoma. Further studies are needed to evaluate whether ghrelin affects the prevalence of obesity in patients with prolactinoma. (J Turk Ger Gynecol Assoc 2015; 16: 86-90) Keywords: Hyperprolactinemia, ghrelin, weight gain Received: 19 February 2015 Accepted: 24 March 2015 Hyperprolactinemia has no effect on plasma ghrelin levels in patients with prolactinoma

show abstract

Blockage of ghrelin-induced prolactin secretion in women by bromocriptine

Cited by 14 publications

References 29 publications

The relationship between gut and adipose hormones, and reproduction

The relationship between gut and adipose hormones, and reproduction

The Relationship of Appetitive, Reproductive and Posterior Pituitary Hormones to Alcoholism and Craving in Humans

Hyperprolactinemia has no effect on plasma ghrelin levels in patients with prolactinoma

Contact Info

Product

Resources

About